Scarica l'app Stockscreener
0.3255
2.04%
0.0065
Dopo l'orario di chiusura:
.32
-0.0055
-1.69%
Precedente Chiudi:
$0.319
Aprire:
$0.317
Volume 24 ore:
2.71M
Relative Volume:
0.14
Capitalizzazione di mercato:
$4.88M
Reddito:
-
Utile/perdita netta:
$-12.89M
Rapporto P/E:
-0.1287
EPS:
-2.53
Flusso di cassa netto:
$-11.95M
1 W Prestazione:
+13.45%
1M Prestazione:
-34.89%
6M Prestazione:
-76.58%
1 anno Prestazione:
-86.88%
Intervallo 1D:
$0.3067
$0.344
Intervallo di 1 settimana:
$0.3067
$0.661
Portata 52W:
$0.26
$2.55
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Confronta PSTV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.3255 | 4.88M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | D. Boral Capital | Buy |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com
Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa
Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus: Q1 Earnings Snapshot - New Haven Register
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks
Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus
Earnings Flash (PSTV) Plus Therapeutics Reports Q1 Loss $-1.19 Per Share, vs. FactSet Est of $-0.25 - marketscreener.com
Plus Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - The Manila Times
PLUS THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Should Plus Therapeutics Inc (NASDAQ: PSTV) Investors Be Concerned? - Stocksregister
DeFi Technologies Provides Monthly Corporate Update: Valour Reports C$1.18 Billion (US$819 Million) AUM, and Record Monthly Net Inflows of C$56 Million (US$38.8 Million) in December 2024 - The Globe and Mail
3 No-Brainer Cloud Computing Stocks to Buy Right Now - The Globe and Mail
Plus Therapeutics recives Nasdaq delinquency notice - MSN
Plus Therapeutics, Inc. Receives Notification of Deficiency from - GuruFocus
Plus Therapeutics (PSTV) Faces Nasdaq Compliance Challenge - GuruFocus
Plus Therapeutics Faces Nasdaq Compliance Notice - TipRanks
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q | PSTV Stock News - GuruFocus
Plus Therapeutics, Inc. Receives Notification of Deficiency - GlobeNewswire
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - TradingView
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN
Plus Therapeutics Receives Nasdaq Delisting Notice - TipRanks
Corpay Stock Jumps 25% in a Year: Here's What You Should Know - The Globe and Mail
Tesla Stock Powers Up for Fourth Straight Week of Gains - The Globe and Mail
Plus Therapeutics Delays Quarterly Report Filing - TipRanks
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN
Plus Therapeutics reports progress in CNS cancer therapy By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Con - GuruFocus
Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in - GuruFocus
Plus Therapeutics Presents Promising ReSPECT Trial Data on REYOBIQ for Leptomeningeal Metastases at 2025 Nuclear Medicine and Neurooncology Conference - Nasdaq
Plus Therapeutics reports progress in CNS cancer therapy - Investing.com
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and - GlobeNewswire
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - TradingView
Plus Therapeutics (PSTV) Expected to Announce Earnings on Wednesday - Defense World
Leptomeningeal Metastases Pipeline 2025: Key Companies, MOA, - openPR.com
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World
Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World
Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus
Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):